Key result
NNRS and quality of life-OSS independently predict persistently elevated NT-proBNP at 12 months.
Why the study?
The authors sought to validate the NT-proBNP nonresponse score derived from the PROTECT and BATTLESCARRED studies against standard health status measures for predicting natriuretic peptide responses in HFrEF.
Does the NT-proBNP nonresponse score (NNRS) and health status measures predict persistently elevated NT-proBNP at 12 months in patients with HFrEF?
Cohort (n=877)
Does the NT-proBNP nonresponse score (NNRS) and health status measures predict persistently elevated NT-proBNP at 12 months in patients with HFrEF?
Answers are grounded in this paper and cite their sources.
The NT-proBNP nonresponse score and KCCQ-OSS independently predict persistently elevated NT-proBNP at 12 months in patients with HFrEF.
BACKGROUND: We aim to validate NT-proBNP nonresponse score (NNRS) previously derived from the PROTECT and BATTLESCARRED studies in comparison with standard health status measures in predicting natriuretic peptide responses in patients with heart failure with reduced ejection fraction. METHODS: Data on the GUIDE-IT trial were used to derive the NNRS based on 4 predictors including baseline NT-proBNP, heart rate, NYHA functional class, and history of atrial fibrillation. The discriminative capacity of the NNRS and health status measures for having NT-proBNP >1,000 pg/mL at 12 months was assessed and compared with baseline or follow-up health status measures including Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OSS), Duke Activity Status Index (DASI), and 6-minute walk distance. Multivariable logistic regression analysis was used to determine the predictive value of the score and health status measures greater than the median values for NT-proBNP response with adjustment for age, sex, body mass index, comorbidities, baseline creatinine and NT-proBNP levels. RESULTS: Among 877 patients, 252 (28.7%) patients had NT-proBNP >1,000 pg/mL at 12 months. The discriminative capacity of the NT-proBNP nonresponse score was 0.72 (95% CI, 0.67-0.77). After adjusting for covariates, only NNRS (P = .044) and KCCQ-OSS (P = .002) remained predictive for NT-proBNP nonresponse at 12 months. CONCLUSION: NT-proBNP nonresponse score and KCCQ-OSS was associated with persistently elevated NT-proBNP 12 months independently of baseline NT-proBNP levels.
No takes yet. Share an insight, caveat, or question.
Chaikijurajai et al. (2025) conducted a cohort in Heart failure with reduced ejection fraction (n=877). NT-proBNP nonresponse score (NNRS) and KCCQ-OSS vs. Other health status measures (DASI, 6-minute walk distance) was evaluated on NT-proBNP >1,000 pg/mL at 12 months (Discriminative capacity 0.72, 95% CI 0.67-0.77, p=0.044). The NT-proBNP nonresponse score (NNRS) and quality of life-OSS independently predicted persistently elevated NT-proBNP >1,000 pg/mL at 12 months.
Synapse has enriched 10 related papers. Consider them for comparative context: